Media coverage about Cara Therapeutics (NASDAQ:CARA) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cara Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.4828203186022 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s rankings:

A number of research analysts have commented on the company. Raymond James Financial, Inc. reduced their target price on Cara Therapeutics from $28.00 to $25.00 and set a “market perform” rating on the stock in a report on Thursday, August 3rd. Piper Jaffray Companies set a $27.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a report on Saturday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Cara Therapeutics in a report on Friday, August 4th. BidaskClub downgraded Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Cara Therapeutics in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.46.

Shares of Cara Therapeutics (CARA) traded up $0.11 during trading on Friday, reaching $12.33. The company’s stock had a trading volume of 1,882,933 shares, compared to its average volume of 835,692.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same quarter in the previous year, the company earned ($0.42) earnings per share. sell-side analysts predict that Cara Therapeutics will post -1.72 earnings per share for the current year.

In other news, CEO Derek T. Chalmers sold 16,000 shares of Cara Therapeutics stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total transaction of $202,560.00. Following the transaction, the chief executive officer now directly owns 1,066,292 shares in the company, valued at approximately $13,499,256.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.70% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cara-therapeutics-cara-share-price/1681474.html.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.